JIUYUAN GENE (02566) has released its annual results for the period ended December 31, 2025. The group reported revenue of RMB 1.306 billion. Profit attributable to owners for the year was RMB 138 million, remaining largely stable compared to the previous year. Basic earnings per share were RMB 0.56. The company has proposed a final cash dividend of RMB 0.57 per 10 shares (tax inclusive).

During the reporting period, the company actively completed the launch and promotion of new products, achieving significant results and gaining market access in 20 provinces and municipalities. Furthermore, in the expansion and continuation rounds of two alliance centralized procurement programs, the product Jixinfen® was selected in multiple provinces. This effectively ensures future price stability and provides favorable conditions and confidence for the subsequent scaled cultivation of the product. For the full year, Jixinfen® achieved sales revenue of RMB 11.1 million.

Throughout the period, the company actively promoted both hospital and non-hospital sales channels. The product Jilixin® was included in the eleventh national centralized drug procurement list in November 2025, effectively enhancing patient accessibility. For the full year, Jilixin® achieved sales revenue of RMB 1.8 million.